A lawsuit by the Federal Trade Commission and New York’s attorney general says his company blocked generic rivals after sharply raising the cost of Daraprim.

Original source: https://www.nytimes.com/2020/01/27/business/martin-shkreli-ftc-lawsuit.html?emc=rss&partner=rss